Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
Femasys Inc. (NASDAQ: FEMY) announced its CEO, Kathy Lee-Sepsick, will speak at the South By Southwest (SXSW) 2023 Conference in Austin, Texas, from March 10-19, 2023. She is set to participate in a panel titled “The Post-Roe Fertility Journey” on March 11, 2023, discussing women's health considerations post-Roe regarding fertility management. Femasys focuses on developing minimally invasive technologies for reproductive health, including FemBloc® for permanent birth control and FemaSeed® for infertility. Their marketed products include FemVue® for fallopian tube assessment and FemCerv® for tissue sampling.
- None.
- None.
ATLANTA, March 09, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced today that Kathy Lee-Sepsick, founder, president & chief executive officer, will participate in the South By Southwest (SXSW) 2023 Conference being held in Austin, Texas from March 10-19, 2023.
Kathy Lee-Sepsick will participate in a panel discussion titled “The Post-Roe Fertility Journey” on March 11, 2023 at 10:00 am CT, which will discuss what considerations are needed in women’s health for protection during fertility management and family building in the post-Roe era.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed in the United States, include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
What will Kathy Lee-Sepsick discuss at SXSW 2023?
Where is the SXSW 2023 Conference held?
What is the focus of Femasys Inc.'s product development?
What products does Femasys currently market?
What is the stock symbol for Femasys Inc.?
